

1646

## STERNE, KESSLER, GOLDSTEIN &amp; FOX P.L.L.C.

ATTORNEYS AT LAW

1100 NEW YORK AVENUE, N.W., SUITE 600  
WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE: (202) 371-2540; (202) 371-6566

ROBERT GREENE STERNE  
EDWARD J. KESSLER  
JORGE A. GOLDSTEIN  
SAMUEL L. FOX  
DAVID K.S. CORNWELL  
ROBERT W. ESMOND  
TRACY-GENE G. DURKIN  
MICHELE A. CIMBALA  
MICHAEL B. RAY

ROBERT E. SOKOHL  
ERIC K. STEFFE  
MICHAEL Q. LEE  
JOHN M. COVERT\*  
LINDA E. ALCORN  
RAZ E. FLESHNER  
ROBERT C. MILLONIG  
STEVEN R. LUDWIG  
MICHAEL V. MESSINGER

JUDITH U. KIM  
TIMOTHY J. SHEA, JR.  
DONALD R. MCPHAIL  
PATRICK E. GARRETT  
BARBARA A. PARVIS  
STEPHEN G. WHITESIDE\*  
NOEL B. WHITLEY\*  
JEFFREY T. HELVEY\*  
RICHARD A. DUNNING, JR.


KIMBERLIN L. MORLEY  
RALPH P. ALBRECHT  
HEIDI L. KRAUS\*  
JEFFREY R. KURIN\*  
CARL B. MASSEY, JR.\*  
PATRICK D. O'BRIEN\*  
BRIAN S. ROSENBLUM\*  
LAWRENCE B. BUGAISKY  
CRYSTAL D. SAYLES\*  
EDWARD W. YEE\*

DONALD J. FEATHERSTONE\*\*  
KAREN R. MARKOWICZ\*\*  
GRANT E. REED\*\*  
VICTOR E. JOHNSON\*\*  
SERGE SIRA\*\*  
SUZANNE E. ZISKA\*\*  
BRIAN J. DEL BUONO\*\*  
CAMERON H. TOUSI\*\*  
VINCENT L. CAPUANO\*\*  
DONALD R. BANOWITZ\*\*  
DAVID P. MAIVALD\*\*

\*BAR OTHER THAN D.C.

\*\*REGISTERED PATENT AGENTS

October 9, 1998



Assistant Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Divisional Utility Patent Application  
Appl. No. 09/033,662; Filed: March 3, 1998  
For: **Human Vascular Endothelial Growth Factor 3**  
Inventors: Jing-Shan HU *et al.*  
Our Ref: 1488.1040001/RCM/AJK

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement;
2. 2 pages of Form PTO-1449; and
3. Return postcard.

RECEIVED  
TECH CENTER 1600/2900  
98 OCT 14 AM 7:53

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Assistant Commissioner for Patents  
October 9, 1998  
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Robert C. Millonig  
Attorney for Applicants  
Registration No. 34,395

RCM/AJK/neh  
Enclosures

P:\USERS\AKAMAGE\CASES\1488\104-1\100898-1st.sids-trl  
SKGF Rev. 9/23/98 dcw

44

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HU *et al.*

Appl. No. 09/033,662

Filed: March 3, 1998

For: **Human Vascular Endothelial  
Growth Factor 3**



Art Unit: 1646

Examiner: To be assigned

Atty. Docket: 1488.1040001/RCM/AJK

### First Supplemental Information Disclosure Statement

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on June 22, 1996 in connection with the above-captioned application. Copies of the documents were cited by or submitted to the Office in Application No. 08/469,641, filed June 6, 1995, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

RECEIVED  
TECH CENTER 1600/2900  
98 OCT 14 AM 7:53

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

This First Information Disclosure Statement is being filed within three months of the U.S. filing date or before the mailing date of a first Office Action on the merits. No statement or fee is required.

Consideration of the cited documents and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN, & FOX P.L.L.C.



Robert C. Millonig  
Attorney for Applicants  
Registration No. 34,395

Date: Oct. 9, 1998

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600